385 related articles for article (PubMed ID: 29718532)
1. The subcutaneous implantable cardioverter-defibrillator: A tertiary center experience.
Khazen C; Magnusson P; Flandorfer J; Schukro C
Cardiol J; 2019; 26(5):543-549. PubMed ID: 29718532
[TBL] [Abstract][Full Text] [Related]
2. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
Rudic B; Tülümen E; Berlin V; Röger S; Stach K; Liebe V; El-Battrawy I; Dösch C; Papavassiliu T; Akin I; Borggrefe M; Kuschyk J
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042423
[TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
[TBL] [Abstract][Full Text] [Related]
4. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
[TBL] [Abstract][Full Text] [Related]
5. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry.
Defaye P; Boveda S; Klug D; Beganton F; Piot O; Narayanan K; Périer MC; Gras D; Fauchier L; Bordachar P; Algalarrondo V; Babuty D; Deharo JC; Leclercq C; Marijon E; Sadoul N;
Europace; 2017 Sep; 19(9):1478-1484. PubMed ID: 28340096
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
[TBL] [Abstract][Full Text] [Related]
7. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators.
Ishida Y; Payne JE; Field ME; Gold MR
J Cardiovasc Electrophysiol; 2020 May; 31(5):1195-1201. PubMed ID: 32128931
[TBL] [Abstract][Full Text] [Related]
8. Oversensing issues leading to device extraction: When subcutaneous implantable cardioverter-defibrillator reached a dead-end.
Noel A; Ploux S; Bulliard S; Strik M; Haeberlin A; Welte N; Marchand H; Klotz N; Ritter P; Haïssaguerre M; Bordachar P
Heart Rhythm; 2020 Jan; 17(1):66-74. PubMed ID: 31295585
[TBL] [Abstract][Full Text] [Related]
9. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
10. Implantable cardioverter-defibrillator lead revision following left ventricular assist device implantation.
Black-Maier E; Lewis RK; Rehorn M; Loungani R; Friedman DJ; Frazier-Mills C; Jackson KP; Atwater BD; Milano CA; Schroder JN; Pokorney SD; Piccini JP
J Cardiovasc Electrophysiol; 2020 Jun; 31(6):1509-1518. PubMed ID: 32275340
[TBL] [Abstract][Full Text] [Related]
11. Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique.
Migliore F; Mattesi G; De Franceschi P; Allocca G; Crosato M; Calzolari V; Fantinel M; Ortis B; Facchin D; Daleffe E; Fabris T; Marras E; De Lazzari M; Zanon F; Marcantoni L; Siciliano M; Corrado D; Iliceto S; Bertaglia E; Zecchin M
J Cardiovasc Electrophysiol; 2019 Jun; 30(6):854-864. PubMed ID: 30827041
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes.
Santharam S; Hudsmith L; Thorne S; Clift P; Marshall H; De Bono J
Europace; 2017 Mar; 19(3):407-413. PubMed ID: 27234868
[TBL] [Abstract][Full Text] [Related]
13. Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators: a systematic review and meta-analysis.
Auricchio A; Hudnall JH; Schloss EJ; Sterns LD; Kurita T; Meijer A; Fagan DH; Rogers T
Europace; 2017 Dec; 19(12):1973-1980. PubMed ID: 28340005
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and management of inappropriate therapy in subcutaneous implantable cardioverter defibrillators.
Karnik AA; Helm RH; Monahan KM
J Cardiovasc Electrophysiol; 2019 Mar; 30(3):402-409. PubMed ID: 30576031
[TBL] [Abstract][Full Text] [Related]
15. Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort.
Heidbuchel H; Willems R; Jordaens L; Olshansky B; Carre F; Lozano IF; Wilhelm M; Müssigbrodt A; Huybrechts W; Morgan J; Anfinsen OG; Prior D; Mont L; Mairesse GH; Boveda S; Duru F; Kautzner J; Viskin S; Geelen P; Cygankiewicz I; Hoffmann E; Vandenberghe K; Cannom D; Lampert R
Eur J Prev Cardiol; 2019 May; 26(7):764-775. PubMed ID: 30813818
[TBL] [Abstract][Full Text] [Related]
16. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
17. Implantable Cardioverter Defibrillators in Infants and Toddlers: Indications, Placement, Programming, and Outcomes.
Zahedivash A; Hanisch D; Dubin AM; Trela A; Chubb H; Motonaga KS; Goodyer WR; Maeda K; Reinhartz O; Ma M; Martin E; Ceresnak SR
Circ Arrhythm Electrophysiol; 2022 Feb; 15(2):e010557. PubMed ID: 35089800
[TBL] [Abstract][Full Text] [Related]
18. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
[TBL] [Abstract][Full Text] [Related]
20. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.
Tan VH; Wilton SB; Kuriachan V; Sumner GL; Exner DV
Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):164-70. PubMed ID: 24446023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
